• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Guidance Update

Guidance Update

July 20, 2020

This occasional column provides summaries of newly released FDA guidances of interest to our readers.

Clinical Trials for BPH Devices

A draft guidance released by the FDA last week contains new recommendations for sponsors conducting clinical trials of devices to treat benign prostatic hyperplasia (BPH), including advice for randomization, endpoints, statistical analysis, patient selection and followup.

The provisions in the draft would replace those in the current final guidance on clinical investigations of devices to treat BPH, dated August 2010. Comments on the draft are due by Sept. 14.

To read the draft guidance, click here: https://bit.ly/32sJSPq.

Trials for Prostate Tissue Ablation

Devicemakers submitting premarket applications for high-intensity ultrasound prostate tissue ablation systems must first conduct clinical trials of the systems under a final regulation the FDA released last week.

Prostate tissue ablation devices of this type present significant risk, the guidance says, and sponsors must comply with Investigational Device Exemption regulations, including IRB review. It also gives advice on study design and duration, inclusion/exclusion criteria, protocols, endpoints and data analysis.

To read the final guidance, click here: https://bit.ly/30oIsTg.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing